Beese Fulmer Investment Management Inc. Purchases 7,231 Shares of Pfizer Inc. (NYSE:PFE)

Beese Fulmer Investment Management Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 14.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 59,050 shares of the biopharmaceutical company’s stock after acquiring an additional 7,231 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Pfizer were worth $1,496,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tallon Kerry Patrick purchased a new stake in shares of Pfizer in the 4th quarter valued at about $509,000. Brighton Jones LLC raised its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. Synergy Asset Management LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at about $63,000. Finally, Crews Bank & Trust purchased a new stake in shares of Pfizer in the 4th quarter valued at about $534,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Trading Up 0.0%

PFE opened at $23.46 on Friday. The stock has a market cap of $133.38 billion, a price-to-earnings ratio of 16.64, a P/E/G ratio of 0.64 and a beta of 0.58. The stock’s 50 day moving average price is $23.12 and its 200-day moving average price is $25.07. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.82 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.33%. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.